Related Experiment Video
Updated: Oct 9, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence
S Holbert1, I Denghien, T Kiechle
1Laboratory of Genomic Biology, Fondation Jean Dausset, Centre d'Etude du Polymorphisme Humain, 75010 Paris, France.
Insights
Huntington's disease (HD) involves huntingtin protein (htt) aggregation. Researchers identified CA150, a protein that interacts with mutated htt, potentially contributing to HD pathogenesis and disease onset variability.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Huntington's disease (HD) is a neurodegenerative disorder characterized by polyglutamine expansion in the huntingtin protein (htt).
- HD pathogenesis involves htt aggregation, formation of neuronal intranuclear inclusions, and altered protein interactions, notably with transcription factors.
Purpose of the Study:
- To identify novel huntingtin-interacting proteins using a yeast two-hybrid screen in a simple model system.
- To investigate the role of the identified interacting protein, CA150, in Huntington's disease pathogenesis.
Main Methods:
- Yeast two-hybrid screen using a Caenorhabditis elegans activation domain library to identify htt-interacting proteins.
- In vitro interaction assays, immunohistochemistry on human brain tissue, and analysis of CA150 repeat length in HD patients.
Main Results:
- A WW domain protein (ZK1127.9) interacting with htt fragments was identified; its human homologue is CA150.
- CA150 expression is significantly increased in HD brain tissue and forms aggregates, partially colocalizing with ubiquitin.
- CA150 repeat length correlates with a small but significant portion of the variability in HD onset age.
Conclusions:
- CA150 interacts with polyglutamine-expanded huntingtin protein.
- Abnormal CA150 expression and its interaction with htt may play a role in Huntington's disease pathogenesis by altering transcription.
Abstract:
Huntington's disease (HD) is a neurodegenerative disease caused by polyglutamine expansion in the protein huntingtin (htt). Pathogenesis in HD appears to involve the formation of ubiquitinated neuronal intranuclear inclusions containing N-terminal mutated htt, abnormal protein interactions, and the aggregate sequestration of a variety of proteins (noticeably, transcription factors). To identify novel htt-interacting proteins in a simple model system, we used a yeast two-hybrid screen with a Caenorhabditis elegans activation domain library. We found a predicted WW domain protein (ZK1127.9) that interacts with N-terminal fragments of htt in two-hybrid tests. A human homologue of ZK1127.9 is CA150, a transcriptional coactivator with a N-terminal insertion that contains an imperfect (Gln-Ala)(38) tract encoded by a polymorphic repeat DNA. CA150 interacted in vitro with full-length htt from lymphoblastoid cells. The expression of CA150, measured immunohistochemically, was markedly increased in human HD brain tissue compared with normal age-matched human brain tissue, and CA150 showed aggregate formation with partial colocalization to ubiquitin-positive aggregates. In 432 HD patients, the CA150 repeat length explains a small, but statistically significant, amount of the variability in the onset age. Our data suggest that abnormal expression of CA150, mediated by interaction with polyglutamine-expanded htt, may alter transcription and have a role in HD pathogenesis.
More Related Videos
Related Concept Videos
Huntington Disease l: Introduction
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
General Transcription Factors
Histone Variants at the Centromere
Enzyme-linked Receptors
Genetic Lingo

